Diagnosis and treatment of recurrent high-grade astrocytoma

Journal of Clinical Oncology

Volumn 24, Issue 8, 2006, Pages 1273-1280

  Butowski, Nicholas A ^a   Sneed, Patricia K ^a   Chang, Susan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CC 5103; CILENGITIDE; EDOTECARIN; ETOPOSIDE; EVEROLIMUS; FR 901228; GEFITINIB; GIMATECAN; GW 86034; IMATINIB; IRINOTECAN; LAPATINIB; LONAFARNIB; NITROSOUREA; ONCOLYTIC VIRUS; PACLITAXEL; PE 38; PSEUDOMONAS EXOTOXIN; R 111577; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ASTROCYTOMA; CANCER GRADING; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG MECHANISM; GLIOMA; HUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT INDICATION; CENTRAL NERVOUS SYSTEM TUMOR; RADIOTHERAPY; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; ASTROCYTOMA; CENTRAL NERVOUS SYSTEM NEOPLASMS; GLIOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY;

EID: 33644856814     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.7522     Document Type: Review

References (87)

1. Cha S: Perfusion MR imaging of brain tumors. Top Magn Reson Imaging 15:279-289, 2004
2. Cha S: Update on brain tumor imaging. Curr Neurol Neurosci Rep 5:169-177, 2005
3. Parney IF, Kunwar S, McDermott M, et al: Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 102:267-275, 2005
4. Graves EE, Nelson SJ, Vigneron DB, et al: Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR Am J Neuroradiol 22:613-624, 2001
5. Smith JS, Cha S, Mayo MC, et al: Serial diffusion-weighted magnetic resonance imaging in cases of glioma: Distinguishing tumor recurrence from postresection injury. J Neurosurg 103:428-438, 2005
6. Meyerand ME, Pipas JM, Mamourian A, et al: Classification of biopsy-confirmed brain tumors using single-voxel MR spectroscopy. AJNR Am J Neuroradiol 20:117-123, 1999
7. Rabinov JD, Lee PL, Barker FG, et al: In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: Initial experience. Radiology 225:871-879, 2002
8. Jacobs AH, Kracht LW, Gossmann A, et al: Imaging in neurooncology. NeuroRx 2:333-347, 2005
9. Dowling C, Bollen AW, Noworolski SM, et al: Preoperative proton MR spectroscopic imaging of brain tumors: Correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol 22:604-612, 2001
10. Hein PA, Eskey CJ, Dunn JF, et al: Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: Tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 25:201-209, 2004
11. Sinha S, Bastin ME, Wardlaw JM, et al: Effects of dexamethasone on peritumoural oedematous brain: A DT-MRI study. J Neurol Neurosurg Psychiatry 75:1632-1635, 2004
12. Henry RG, Vigneron DB, Fischbein NJ, et al: Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. AJNR Am J Neuroradiol 21:357-366, 2000
13. Law M, Yang S, Wang H, et al: Glioma grading: Sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24:1989-1998, 2003
14. Lee MC, Cha S, Chang SM, et al: Dynamic susceptibility contrast perfusion imaging of radiation effects in normal-appearing brain tissue: Changes in the first-pass and recirculation phases. J Magn Reson Imaging 21:683-693, 2005
15. Chao ST, Suh JH, Raja S, et al: The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 96:191-197, 2001
16. Wong TZ, van der Westhuizen GJ, Coleman RE: Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 12:615-626, 2002
17. Tsuyuguchi N, Takami T, Sunada I, et al: Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery - in malignant glioma. Ann Nucl Med 18:291-296, 2004
18. Rachinger W, Goetz C, Popperl G, et al: Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 57:505-511, 2005
19. Pinsker M, Lumenta C: Experiences with reoperation on recurrent glioblastoma multiforme. Zentralbl Neurochir 62:43-47, 2001
20. Veninga T, Langendijk HA, Slotman BJ, et al: Reirradiation of primary brain tumours: Survival, clinical response and prognostic factors. Radiother Oncol 59:127-137, 2001
21. Bauman GS, Sneed PK, Wara WM, et al: Reirradiation of primary CNS tumors. Int J Radiat Oncol Biol Phys 36:433-441, 1996
22. Voynov G, Kaufman S, Hong T, et al: Treatment of recurrent malignant gliomas with stereotactic intensity modulated radiation therapy. Am J Clin Oncol 25:606-611, 2002
23. Sneed PK, McDermott MW, Gutin PH: Interstitial brachytherapy procedures for brain tumors. Semin Surg Oncol 13:157-166, 1997
24. Shrieve DC, Alexander E III, Wen PY, et al: Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 36:275-284, 1995
25. Chan TA, Weingart JD, Parisi M, et al: Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys 62:1133-1139, 2005
26. Gaspar LE, Zamorano LJ, Shamsa F, et al: Permanent 125-iodine implants for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 43:977-982, 1999
27. Larson DA, Suplica JM, Chang SM, et al: Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neuro-oncol 6:119-126, 2004
28. Patel S, Breneman JC, Warnick RE, et al: Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme. Neurosurgery 46:1123-1130, 2000
29. Cho KH, Hall WA, Gerbi BJ, et al: Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys 45:1133-1141, 1999
30. Combs SE, Widmer V, Thilmann C, et al: Stereotactic radiosurgery (SRS): Treatment option for recurrent glioblastoma multiforme (GBM). Cancer 104:2457-2465, 2005
31. Kondziolka D, Flickinger JC, Bissonette DJ, et al: Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery 41:776-785, 1997
32. Hudes RS, Corn BW, Werner-Wasik M, et al: A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 43:293-298, 1999
33. Lederman G, Wronski M, Arbit E, et al: Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol 23:155-159, 2000
34. Shepherd SF, Laing RW, Cosgrove VP, et al: Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys 37:393-398, 1997
35. Vordermark D, Kolbl O, Ruprecht K, et al: Hypofractionated stereotactic re-irradiation: Treatment option in recurrent malignant glioma. BMC Cancer 5:55, 2005
36. Stylii SS, Kaye AH, Macgregor L, et al: Photodynamic therapy of high grade glioma: Long term survival. J Clin Neurosci 12:389-398, 2005
37. Stupp R, van den Bent MJ, Hegi ME: Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 5:198-206, 2005
38. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
39. Stupp R, Pavlidis N, Jelic S: ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma. Ann Oncol 16:i64-i65, 2005 (suppl 1)
40. Hau P, Baumgart U, Pfeifer K, et al: Salvage therapy in patients with glioblastoma: Is there any benefit? Cancer 98:2678-2686, 2003
41. Rosenthal MA, Ashley DL, Cher L: BCNU as second line therapy for recurrent high-grade glioma previously treated with temozolomide. J Clin Neurosci 11:374-375, 2004
42. Franceschi E, Cavallo G, Scopece L, et al: Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. Br J Cancer 91:1038-1044, 2004
43. Reardon DA, Quinn JA, Vredenburgh J, et al: Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 103:329-338, 2005
44. Brandes AA, Tosoni A, Basso U, et al: Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: A phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22:4779-4786, 2004
45. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
46. Bobola MS, Silber JR, Ellenbogen RG, et al: O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines. Clin Cancer Res 11:2747-2755, 2005
47. Kaina B, Christmann M: DNA repair in resistance to alkylating anticancer drugs. Int J Clin Pharmacol Ther 40:354-367, 2002
48. Tentori L, Leonetti C, Scarsella M, et al: Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. Int J Oncol 26:415-422, 2005
49. Tentori L, Graziani G: Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 52:25-33, 2005
50. Ueki K: Oligodendroglioma: Impact of molecular biology on its definition, diagnosis and management. Neuropathology 25:247-253, 2005
51. Butowski N, Chang SM: Small molecule and monoclonal antibody therapies in neurooncology. Cancer Control 12:116-124, 2005
52. Newton HB: Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors: Part 1 - Growth factor and Ras signaling pathways. Expert Rev Anticancer Ther 3:595-614, 2003
53. Newton HB: Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors: Part 2 - PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev Anticancer Ther 4:105-128, 2004
54. Newton HB: Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors: Part 3 - Brain tumor invasiveness. Expert Rev Anticancer Ther 4:803-821, 2004
55. Newton HB: Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors: Part 4 - p53 signaling pathway. Expert Rev Anticancer Ther 5:177-191, 2005
56. Newton HB: Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors: Part 5 - Apoptosis and cell cycle. Expert Rev Anticancer Ther 5:355-378, 2005
57. Raizer JJ: HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol 74:77-86, 2005
58. Rich JN, Reardon DA, Peery T, et al: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133-142, 2004
59. Cloughesy TF, Kuhn J, Robins HI, et al: Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium Study. J Clin Oncol 23:6647-6656, 2005
60. Schmelzte T, Hall MN: TOR, a central controller of cell growth. Cell 103:253-262, 2000
61. Chang SM, Kuhn J, Wen P, et al: Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs 22:427-435, 2004
62. Chang SM, Wen P, Cloughesy T, et al: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23:357-361, 2005
63. Galanis E, Buckner JC, Maurer MJ, et al: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 23:5294-5304, 2005
64. Kaur B, Tan C, Brat DJ, et al: Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol 70:229-243, 2004
65. Chan AS, Leung SY, Wong MP, et al: Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 22:816-826, 1998
66. Bicaku E, Acevedo-Duncan M: Ultrastructural study of protein kinase C-beta II localization during the cell cycle of human glioma cells. Tissue Cell 33:55-62, 2001
67. Gescher A: Analogs of staurosporine: Potential anticancer drugs? Gen Pharmacol 31:721-728, 1998
68. Jarvis WD, Grant S: Protein kinase C targeting in antineoplastic treatment strategies. Invest New Drugs 17:227-240, 1999
69. Parker PJ: Inhibition of protein kinase C - Do we, can we, and should we? Pharmacol Ther 82:263-267, 1999
70. Keyes KA, Mann L, Sherman M, et al: LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 53:133-140, 2004
71. Teicher BA, Menon K, Alvarez E, et al: Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human T98G glioblastoma multiforme xenografts. Clin Cancer Res 7:634-640, 2001
72. Fine HA, Kim L, Royce R, et al: Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. J Clin Oncol 23:115s, 2005 (suppl; abstr 1504)
73. Plate KH: Mechanisms of angiogenesis in the brain. J Neuropathol Exp Neurol 58:313-320, 1999
74. Fine HA, Figg WD, Jaeckle K, et al: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708-715, 2000
75. Teo SK: Properties of thalidomide and its analogues: Implications for anticancer therapy. AAPS J 7:E14-E19, 2005
76. Sawa H, Murakami H, Kumagai M, et al: Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol (Berl) 107:523-531, 2004
77. Eyupoglu IY, Hahnen E, Buslei R, et al: Suberoylanilide hydroxamic acid (SAHA) has potent antiglioma properties in vitro, ex vivo and in vivo. J Neurochem 93:992-999, 2005
78. Chiocca EA, Broaddus WC, Gillies GT, et al: Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neurooncology. J Neurooncol 69:101-117, 2004
79. Brem H, Piantadosi S, Burger PC, et al: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas: The Polymer-brain Tumor Treatment Group. Lancet 345:1008-1012, 1995
80. Sampson JH, Reardon DA, Friedman AH, et al: Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: Case study. Neuro-oncol 7:90-96, 2005
81. Sampson JH, Akabani G, Archer GE, et al: Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 65:27-35, 2003
82. Lidar Z, Mardor Y, Jonas T, et al: Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: A phase I/II clinical study. J Neurosurg 100:472-479, 2004
83. Lawler SE, Peruzzi PP, Chiocca EA: Genetic strategies for brain tumor therapy. Cancer Gene Ther: September 2, 2005 lepub ahead of print]
84. Westphal M, Black PM: Perspectives of cellular and molecular neurosurgery. J Neurooncol 70:255-269, 2004
85. Khan-Farooqi HR, Prins RM, Liau LM: Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies. Neurol Res 27:692-702, 2005
86. Veiseh O, Sun C, Gunn J, et al: Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett 5:1003-1008, 2005
87. Kircher MF, Mahmood U, King RS, et al: A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 63:8122-8125, 2003